220
Participants
Start Date
March 1, 2023
Primary Completion Date
February 1, 2026
Study Completion Date
December 1, 2026
apantamide+docetaxel+ADT
Apantamide, 240 mg (4 × 60 mg tablets), once a day, orally; ADT regimen was treated with gonadotropin releasing hormone analog (GnRHa), including GnRHa agonist or GnRHa antagonist. The type, frequency and dose of ADT to be used in each research center are determined by the investigator; The treatment of docetaxel was started within 6 weeks after the treatment of apantamide and ADT. The single dose of docetaxel was 75 mg/m2, intravenous drip for 1 hour, repeated every 3 weeks, and docetaxel lasted for 6 cycles.
apantamide+ADT treatment
apantamide+ADT treatment
RECRUITING
Qilu hospital, Jinan
Qilu Hospital of Shandong University
OTHER